Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works

The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging

Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,531 · see citing works

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · see citing works

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · see citing works

Abiraterone and Increased Survival in Metastatic Prostate Cancer

de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · see citing works

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665 · see citing works

Integrative Clinical Genomics of Advanced Prostate Cancer

Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645 · see citing works

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · see citing works

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318 · see citing works

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

Ahmed, H. U., Bosaily, A. E., Brown, L. C., Gabe, R., Kaplan, R. S., Parmar, M., Collaço‐Moraes, Y., Ward, K., Hindley, R. G., Freeman, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32401-1 · Cited by 3,292 · see citing works

The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000530 · Cited by 3,246 · see citing works

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G. O., Hindley, R. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801993 · Cited by 3,102 · see citing works

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · see citing works

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,908 · see citing works

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710 · see citing works

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

D'Amico, A., Whittington, R., Malkowicz, S., Schultz, D., Blank, K., Broderick, G., Tomaszewski, J., Renshaw, A., Kaplan, I., Beard, C., et al. (1998) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.280.11.969 · Cited by 2,697 · see citing works

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

Hamdy, F. C., Donovan, J., Lane, J. A., Mason, M. D., Metcalfe, C. D., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,642 · see citing works

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Fizazi, K. S., Tran, N., Fein, L. E., Matsubara, N., Rodríguez-Antolín, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,326 · see citing works

Olaparib for Metastatic Castration-Resistant Prostate Cancer

de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323 · see citing works

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276 · see citing works

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185 · see citing works

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P. A., Rutherford, N. K., Martin, J. M., Frydenberg, M., Ramdave, S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30314-7 · Cited by 2,067 · see citing works

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,983 · see citing works

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Fizazi, K. S., Carducci, M. A., Smith, M. R., Damião, R., Brown, J. E., Karsh, L. I., Milecki, P., Shore, N. D., Rader, M. E., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,974 · see citing works

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

Palma, D. A., Olson, R. A., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C. J. A., Mulroy, L. A., Lock, M. I., Rodrigues, G., Yaremko, B., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,865 · see citing works

Abiraterone for prostate cancer not previously treated with hormone therapy

James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801 · see citing works

Radical Prostatectomy versus Observation for Localized Prostate Cancer

Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P. E., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,767 · see citing works

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680 · see citing works

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903835 · Cited by 1,633 · see citing works

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Zappa, M., Nelen, V., KWIATKOWSKI, M. K., Lujan, M., Määttänen, L., Lilja, H. G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60525-0 · Cited by 1,566 · see citing works

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564 · see citing works

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

Cornford, P. A., Joaquim Bellmunt, B., Bolla, M., Briers, E., Santis, M. D., Gross, T., Henry, A. M., Joniau, S., Lam, T. B. L., Mason, M. D., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.08.002 · Cited by 1,440 · see citing works

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369 · see citing works

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial

Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., Bruycker, A. D., Lambert, B., Delrue, L. J., Bultijnck, R., Claeys, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,362 · see citing works

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344 · see citing works

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Parker, C., James, N. D., Brawley, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32486-3 · Cited by 1,292 · see citing works

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J. M., Villers, A. A., Azad, A., Alcaraz, A., Alekseev, B. Y., Iguchi, T., Shore, N. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00799 · Cited by 1,219 · see citing works

Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer

Fred Saad, C., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J., Goas, J. A., & Zheng, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh141 · Cited by 1,199 · see citing works

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Kyriakopoulos, C. E., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,108 · see citing works

Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study

Rouvière, O., Puech, P., Renard‐Penna, R., Claudon, M., Roy, C., Mège‐Lechevallier, F., Decaussin‐Petrucci, M., Dubreuil-Chambardel, M., Magaud, L., Remontet, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30569-2 · Cited by 1,093 · see citing works

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Hussain, M., Fizazi, K. S., Fred Saad, C., Rathenborg, P., Shore, N. D., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,041 · see citing works

Duration of Androgen Suppression in the Treatment of Prostate Cancer

Bolla, M., de Reijke, T. M., van Tienhoven, G., van den Bergh, A. C. M., Oddens, J. R., Poortmans, P. M., Gez, E., Kil, P. J. M., Akdaş, A., Soete, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810095 · Cited by 970 · see citing works

Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis

Perera, M., Papa, N. P., Roberts, M. J., Williams, M., Udovicich, C., Vela, I., Christidis, D., Bolton, D. M., Hofman, M. S., Lawrentschuk, N., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.01.049 · Cited by 964 · see citing works

Oligometastases revisited

Weichselbaum, R. R., & Hellmän, S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.44 · Cited by 947 · see citing works

Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

Thompson, I. M., Ankerst, D. P., Chen, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 941 · see citing works

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930 · see citing works

Palliative Radiotherapy Trials for Bone Metastases: A Systematic Review

Chow, E., Harris, K., Fan, G., Tsao, M. N., & Sze, W. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.5281 · Cited by 907 · see citing works

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

Widmark, A., Klepp, O., Solberg, A., Damber, J. ‐., Angelsen, A., Fransson, P., Lund, J., Taşdemir, İ., Høyer, M., Wiklund, F. E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61815-2 · Cited by 878 · see citing works

Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer

Castro, E., Goh, C. L., Olmos, D., Saunders, E. J., Leongamornlert, D. A., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 854 · see citing works

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Fizazi, K. S., Tran, N., Fein, L. E., Matsubara, N., Rodríguez-Antolín, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30082-8 · Cited by 842 · see citing works

Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95

Wiegel, T., Bottke, D., Steiner, U., Siegmann, A. D., Golz, R., Störkel, S., Willich, N., Semjonow, A., Souchon, R., Stöckle, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9563 · Cited by 825 · see citing works

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study

Cuzick, J. M., Swanson, G. P., Fisher, G., Brothman, A. R., Berney, D. M., Reid, J., Mesher, D., Speights, V. O., Stankiewicz, E., Foster, C. S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70295-3 · Cited by 792 · see citing works

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gravis, G., Fizazi, K. S., Joly, F., Oudard, S. M., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 746 · see citing works

Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02

Hanks, G. E., Pajak, T. F., Porter, A. T., Grignon, D. J., Brereton, H. D., Venkatesan, V., Horwitz, E. M., Lawton, C. A., Rosenthal, S. A., Sandler, H. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.023 · Cited by 688 · see citing works

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., Rathkopf, D., Morris, M. J., Danila, D. C., Slovin, S. F., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5801 · Cited by 667 · see citing works

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

de Wit, R., Bono, J. S. D., Sternberg, C. N., Fizazi, K. S., TOMBAL, B. F., Wülfing, C., Kramer, G., Eymard, J., Bamias, A., Carles, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911206 · Cited by 666 · see citing works

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., Sartor, O., Patel, M. P., Bahary, J.-P., Zietman, A. L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607529 · Cited by 663 · see citing works

Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610

Roach, M., Bae, K., Speight, J. L., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C. A., Valicenti, R. K., Grignon, D. J., & Pilepich, M. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9881 · Cited by 649 · see citing works

ESMO-magnitude of clinical benefit scale version 1.1

Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641 · see citing works

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 637 · see citing works

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

Warde, P. R., Mason, M., Ding, K., Kirkbride, P., Brundage, M., Cowan, R. A., Gospodarowicz, M. K., Sanders, K., Kostashuk, E. C., Swanson, G. P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61095-7 · Cited by 579 · see citing works

Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial

Boevé, L. M. S., Hulshof, M. C. C. M., Vis, A. N., Zwinderman, A. H., Twisk, J. W. R., Witjes, W. P. J., Delaere, K. P. J., van Moorselaar, R. J. A., Verhagen, P. C. M. S., & van Andel, G. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.008 · Cited by 573 · see citing works

Bone health in cancer: ESMO Clinical Practice Guidelines

Coleman, R. E., Hadji, P., Body, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.019 · Cited by 550 · see citing works

Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review

den Broeck, T. V., van den Bergh, R. C. N., Arfi, N., Gross, T., Moris, L., Briers, E., Cumberbatch, M. G. K., Santis, M. D., Derya Tilki, A., Fanti, S., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.10.011 · Cited by 525 · see citing works

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

Crook, J. M., O'Callaghan, C. J., Duncan, G. G., Dearnaley, D. P., Higano, C. S., Horwitz, E. M., Frymire, E., Malone, S. C., Chin, J. L., Nabid, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201546 · Cited by 498 · see citing works

Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up

Bill‐Axelson, A., Holmberg, L., Garmo, H., Taari, K., Busch, C., Nordling, S., Häggman, M., Andersson, S., Andrén, O., Steineck, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807801 · Cited by 494 · see citing works

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

Incrocci, L., Wortel, R. C., Alemayehu, W. G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30070-5 · Cited by 485 · see citing works

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Smith, M. R., Parker, C. C., Fred Saad, C., Miller, K., TOMBAL, B. F., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E. R., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30860-x · Cited by 415 · see citing works

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

Vale, C. L., Burdett, S., Rydzewska, L. H. M., Albiges, L. K., Clarke, N. W., Fisher, D. J., Fizazi, K. S., Gravis, G., James, N. D., Mason, M. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00489-1 · Cited by 406 · see citing works

A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy

Zumsteg, Z. S., Spratt, D. E., Pei, I., Zhang, Z., Yamada, Y. J., Kollmeier, M. A., & Zeléfsky, M. J. (2013) · European Urology · doi:10.1016/j.eururo.2013.03.033 · Cited by 397 · see citing works

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

Armstrong, A. J., Halabi, S., Luo, J., Nanus, D. M., Giannakakou, P., Szmulewitz, R. Z., Danila, D. C., Healy, P. N., Anand, M., Rothwell, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01731 · Cited by 364 · see citing works

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

Khalaf, D. J., Annala, M., Taavitsainen, S., Finch, D. L., Oja, C. D., Vergidis, J., Zulfiqar, M., Sunderland, K., Azad, A., Kollmannsberger, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30688-6 · Cited by 362 · see citing works

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer

Michalski, J. M., Moughan, J., Purdy, J. A., Bosch, W. R., Bruner, D. W., Bahary, J.-P., Lau, H., Duclos, M., Parliament, M. B., Morton, G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0039 · Cited by 357 · see citing works

Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative‘s Neuro-Oncology Disease Site Group

Loblaw, D. A., Perry, J., Chambers, A., & Laperrière, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.067 · Cited by 325 · see citing works

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial

Dearnaley, D. P., Syndikus, I., Sumo, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70293-5 · Cited by 310 · see citing works

Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer

Abdollah, F., Karnes, R. J., Suardi, N. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.7893 · Cited by 292 · see citing works

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

Vickers, A. J., Ulmert, D., Sjoberg, D. D., Bennette, C., Björk, T., Gerdtsson, A., Manjer, J., Nilsson, P. M., Dahlin, A., Bjartell, A. S., et al. (2013) · BMJ · doi:10.1136/bmj.f2023 · Cited by 283 · see citing works

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Fizazi, K. S., Faivre, L., Lesaunier, F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00011-x · Cited by 243 · see citing works

Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group

Mandelker, D. L., Donoghue, M. T. A., Talukdar, S., Bandlamudi, C., Srinivasan, P., Vivek, M., Jezdic, S., Hanson, H., Snape, K. M. G., Kulkarni, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz136 · Cited by 242 · see citing works

Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases

Nguyen, Q., Chun, S. G., Chow, E., Komaki, R. U., Liao, Z. X., Zacharia, R., Szeto, B. K., Welsh, J. W., Hahn, S. M., Fuller, C. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0192 · Cited by 221 · see citing works

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Duchesne, G. M., Woo, H. H., Bassett, J. K., Bowe, S. J., D’Este, C. A., Frydenberg, M., King, M. T., Ledwich, L., Loblaw, A., Malone, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00107-8 · Cited by 220 · see citing works

Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis

Zhao, S. G., Chang, S. L., Spratt, D. E., Erho, N., Yu, M., Ashab, H. A.-D., Alshalalfa, M., Speers, C. W., Tomlins, S. A., Davicioni, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30491-0 · Cited by 213 · see citing works

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial

Nabid, A., Carrier, N., Martin, A., Bahary, J.-P., Lemaire, C., Vass, S., Bahoric, B., Archambault, R., Vincent, F., Bettahar, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.06.018 · Cited by 213 · see citing works

The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy

Zumsteg, Z. S., Spratt, D. E., Romesser, P. B., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.09.028 · Cited by 206 · see citing works

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017

Giri, V. N., Knudsen, K. E., Kelly, W. K., Abida, W. M., Andriole, G. L., Bangma, C. H., Bekelman, J. E., Benson, M. C., Blanco, A. M., Burnett, A. L. “., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.1173 · Cited by 191 · see citing works

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Szmulewitz, R. Z., Peer, C. J., Ibraheem, A. F., Martinez, E., Kozloff, M. F., Carthon, B. C., Harvey, R. D., Fishkin, P. A. S., Yong, W. P., Chiong, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4381 · Cited by 183 · see citing works

Active surveillance for prostate cancer: a narrative review of clinical guidelines

Bruinsma, S. M., Bangma, C. H., Carroll, P. R., et al. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2015.313 · Cited by 182 · see citing works

Assessing Individual Risk for Prostate Cancer

Nam, R. K., Toi, A., Klotz, L. H., Trachtenberg, J., Jewett, M. A. S., Appu, S., Loblaw, D. A., Sugar, L., Narod, S. A., & Kattan, M. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6450 · Cited by 175 · see citing works

68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review

Corfield, J. M., Perera, M., Bolton, D. M., & Lawrentschuk, N. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2182-1 · Cited by 167 · see citing works

Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer

von Eyben, F. E., & Kairemo, K. (2013) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000040 · Cited by 164 · see citing works

Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial

Pollack, A. S., Karrison, T. G., Balogh, A., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.08.052 · Cited by 153 · see citing works

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis

Tucci, M., Bertaglia, V., Vignani, F., Buttigliero, C., Fiori, C., Porpiglia, F., Scagliotti, G. V., & Maïo, M. D. (2015) · European Urology · doi:10.1016/j.eururo.2015.09.013 · Cited by 119 · see citing works

A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).

Sandler, H. M., Hu, C., Rosenthal, S. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba5002 · Cited by 98 · see citing works

A Randomised Phase 2 Trial of Dexamethasone Versus Prednisolone in Castration-resistant Prostate Cancer

Venkitaraman, R., Lorente, D., Murthy, V., Thomas, K., Parker, L., Ahiabor, R., Dearnaley, D. P., Huddart, R. A., Bono, J. S. D., & Parker, C. C. (2014) · European Urology · doi:10.1016/j.eururo.2014.10.004 · Cited by 96 · see citing works

Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis

Feyerabend, S., Fred Saad, C., Li, T. M. W. Y., Ito, T., Diels, J., Sanden, S. V., Porre, P. D., Roïz, J., Abògúnr̀in, Ṣ., Koufopoulou, M., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.010 · Cited by 96 · see citing works

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis

Vale, C. L., Fisher, D. J., White, I. R., Carpenter, J. R., Burdett, S., Clarke, N. W., Fizazi, K. S., Gravis, G., James, N. D., Mason, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy071 · Cited by 85 · see citing works

Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment

Kinney, A. Y., Vernon, S. W., Frankowski, R. F., Weber, D. M., Bitsura, J. M., & Vogel, V. G. (1995) · Cancer · doi:10.1002/1097-0142(19950701)76:1 · Cited by 68 · see citing works

Comparative Oncologic and Toxicity Outcomes of Salvage Radical Prostatectomy Versus Nonsurgical Therapies for Radiorecurrent Prostate Cancer: A Meta–Regression Analysis

Philippou, Y., Parker, R. A., Volanis, D., et al. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.09.004 · Cited by 49 · see citing works

A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12.

Ahlgren, G., Flodgren, P., Tammela, T. L. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.5001 · Cited by 16 · see citing works

A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.

Kellokumpu-Lehtinen, P.-L. I., Hjälm-Eriksson, M., Åström, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5000 · Cited by 12 · see citing works

Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer

Kothari, G., Ost, P., Cheung, P., Blanchard, P., Tree, A. C., van As, N. J., Lo, S. S.-M., Moghanaki, D. M., Loblaw, A., & Siva, S. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0791-5 · Cited by 12 · see citing works

Clinical pathway improves implementation of evidence‐based strategies for the management of androgen deprivation therapy‐induced side effects in men with prostate cancer

Bultijnck, R., de Caveye, I. V., Rammant, E., Everaert, S., Lumen, N., Decaestecker, K., Fonteyne, V., Deforche, B. I., & Ost, P. (2017) · British Journal of Urology · doi:10.1111/bju.14086 · Cited by 11 · see citing works

Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475).

Carrié, C., Magné, N., Burban-Provost, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.5001 · Cited by 7 · see citing works

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214676 · Cited by 449 · see citing works

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01653-2 · Cited by 362 · see citing works

Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.04.002 · Cited by 130 · see citing works

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00158-4 · Cited by 125 · see citing works

Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents

Fizazi, K., & Gillessen, S. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.015 · Cited by 119 · see citing works

Diagnostic Quality Model (DQM): an integrated framework for the assessment of diagnostic quality when using AI/ML

Lennerz, J. K., Salgado, R., Kim, G. E., Sirintrapun, S. J., Thierauf, J. C., Singh, A., Indave, I., Bard, A., Weissinger, S. E., Heher, Y. K., et al. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1151 · Cited by 29 · see citing works

Circulating Tumor Cells in Prostate Cancer

Tariki, M. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-69879-9_6

Androgen Receptor Antagonists for the Treatment of Prostate Cancer

Li, Z. (2012) · Yaoxue jinzhan

[ASC-J9 for castration-resistant prostate cancer].

Yamashita, S., & Arai, Y. (2014) · PubMed

Dynamic Profiling of Exosomal microRNAs in Blood Plasma of Patients with Castration-Resistant Prostate Cancer

Pudova, E. A., Kobelyatskaya, A. A., Katunina, I. V., et al. (2022) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1402015 · Cited by 10 · see citing works

Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsies

Eminağa, O., Hinkelammert, R., Abbas, M., et al. (2014) · British Journal of Urology · doi:10.1111/bju.12691 · Cited by 7 · see citing works